Viridian Therapeutics Inc
NASDAQ:VRDN

Watchlist Manager
Viridian Therapeutics Inc Logo
Viridian Therapeutics Inc
NASDAQ:VRDN
Watchlist
Price: 17.05 USD 1.55% Market Closed
Market Cap: 1.4B USD

EV/EBIT
Enterprise Value to EBIT

-2.3
Current
-2.4
Median
4.9
Industry
Higher than median
Lower than industry value

Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.

EV/EBIT
-2.3
=
Enterprise Value
775.2m USD
/
EBIT
-337m USD
EBIT Growth EV/EBIT to Growth
US
Viridian Therapeutics Inc
NASDAQ:VRDN
Average EV/EBIT: 20.5
Negative Multiple: -2.3
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 785.5 N/A N/A
US
Abbvie Inc
NYSE:ABBV
22.9
29%
0.8
US
Amgen Inc
NASDAQ:AMGN
23.9
32%
0.7
US
Gilead Sciences Inc
NASDAQ:GILD
13.6
11%
1.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
26.8
17%
1.6
US
E
Epizyme Inc
F:EPE
Negative Multiple: -558.1 N/A N/A
AU
CSL Ltd
ASX:CSL
22.5
14%
1.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
13.3
11%
1.2
US
S
Seagen Inc
F:SGT
Negative Multiple: -59.3 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -352.8 N/A N/A

EV/EBIT Forward Multiples

Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBIT
hidden
2-Years Forward
EV/EBIT
hidden
3-Years Forward
EV/EBIT
hidden